Bayer, Pfizer and Ipsen-backed cancer therapeutics developer Pyxis Oncology priced its shares at the top of its range.

Having priced its shares at the top of its range, UChicago spinout Pyxis Oncology suffered a drop on the first day of trading.

The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.

Canon, Kansai Electric Power, Mitsui Fudosan, NEC, NTT Docomo, So-net and T-Gaia were among the investors that scored exits as the CCTV system provider went public.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

SoftBank invested $125m through a $160m private placement as portfolio company and cancer drug developer Exscientia went public in an offering sized at nearly $305m.

The Dundee spinout has raised more than $304m in its IPO in the US, with another $160m secured through a concurrent private placement.

Tencent, Nikon, Amgen and Illumina all scored exits as the DNA sequencing provider's shares popped in the wake of its flotation.